Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity

A retrospective analysis

Robert J Canter, Li Xuan Qin, Robert J. Downey, Murray F. Brennan, Samuel Singer, Robert G. Maki

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

BACKGROUND. The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial. To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity. METHODS. Between 1990 and 2005, 1897 patients with extremity STS were treated and prospectively followed at a single institution. In all, 508 patients (27%) developed lung metastases as the first site of distant recurrence, and 138 (7%) were treated with pulmonary resection. RESULTS. Perioperative chemotherapy was administered to 53 patients (38%). Age at diagnosis and disease-free interval were significantly different between patients who received perioperative chemotherapy and those who did not, whereas sex, grade, size of the primary tumor, depth, histology, number and size of lung metastases, and rate of complete resection were not. The median post-metastasis disease-specific survival was 24 months in patients who were treated with surgery and chemotherapy compared with 33 months in patients who were treated with surgery alone (P = .19). The median postmetastasis pulmonary progression-free survival in the 2 groups was 10 months and 11 months, respectively (P = .63). Multivariate Cox proportional hazards modeling and propensity score analysis revealed no association between perioperative chemotherapy and disease-specific, overall, or pulmonary progression-free survival. CONCLUSIONS. Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.

Original languageEnglish (US)
Pages (from-to)2050-2060
Number of pages11
JournalCancer
Volume110
Issue number9
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Sarcoma
Extremities
Drug Therapy
Lung
Neoplasm Metastasis
Disease-Free Survival
Propensity Score
Selection Bias
Histology
Recurrence
Survival

Keywords

  • Long-term impact
  • Perioperative chemotherapy
  • Pulmonary metastasectomy
  • Soft-tissue sarcoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : A retrospective analysis. / Canter, Robert J; Qin, Li Xuan; Downey, Robert J.; Brennan, Murray F.; Singer, Samuel; Maki, Robert G.

In: Cancer, Vol. 110, No. 9, 01.11.2007, p. 2050-2060.

Research output: Contribution to journalArticle

Canter, Robert J ; Qin, Li Xuan ; Downey, Robert J. ; Brennan, Murray F. ; Singer, Samuel ; Maki, Robert G. / Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : A retrospective analysis. In: Cancer. 2007 ; Vol. 110, No. 9. pp. 2050-2060.
@article{6ad210b1201a4a80a2c7349441851705,
title = "Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: A retrospective analysis",
abstract = "BACKGROUND. The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial. To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity. METHODS. Between 1990 and 2005, 1897 patients with extremity STS were treated and prospectively followed at a single institution. In all, 508 patients (27{\%}) developed lung metastases as the first site of distant recurrence, and 138 (7{\%}) were treated with pulmonary resection. RESULTS. Perioperative chemotherapy was administered to 53 patients (38{\%}). Age at diagnosis and disease-free interval were significantly different between patients who received perioperative chemotherapy and those who did not, whereas sex, grade, size of the primary tumor, depth, histology, number and size of lung metastases, and rate of complete resection were not. The median post-metastasis disease-specific survival was 24 months in patients who were treated with surgery and chemotherapy compared with 33 months in patients who were treated with surgery alone (P = .19). The median postmetastasis pulmonary progression-free survival in the 2 groups was 10 months and 11 months, respectively (P = .63). Multivariate Cox proportional hazards modeling and propensity score analysis revealed no association between perioperative chemotherapy and disease-specific, overall, or pulmonary progression-free survival. CONCLUSIONS. Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.",
keywords = "Long-term impact, Perioperative chemotherapy, Pulmonary metastasectomy, Soft-tissue sarcoma, Survival",
author = "Canter, {Robert J} and Qin, {Li Xuan} and Downey, {Robert J.} and Brennan, {Murray F.} and Samuel Singer and Maki, {Robert G.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1002/cncr.23023",
language = "English (US)",
volume = "110",
pages = "2050--2060",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity

T2 - A retrospective analysis

AU - Canter, Robert J

AU - Qin, Li Xuan

AU - Downey, Robert J.

AU - Brennan, Murray F.

AU - Singer, Samuel

AU - Maki, Robert G.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - BACKGROUND. The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial. To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity. METHODS. Between 1990 and 2005, 1897 patients with extremity STS were treated and prospectively followed at a single institution. In all, 508 patients (27%) developed lung metastases as the first site of distant recurrence, and 138 (7%) were treated with pulmonary resection. RESULTS. Perioperative chemotherapy was administered to 53 patients (38%). Age at diagnosis and disease-free interval were significantly different between patients who received perioperative chemotherapy and those who did not, whereas sex, grade, size of the primary tumor, depth, histology, number and size of lung metastases, and rate of complete resection were not. The median post-metastasis disease-specific survival was 24 months in patients who were treated with surgery and chemotherapy compared with 33 months in patients who were treated with surgery alone (P = .19). The median postmetastasis pulmonary progression-free survival in the 2 groups was 10 months and 11 months, respectively (P = .63). Multivariate Cox proportional hazards modeling and propensity score analysis revealed no association between perioperative chemotherapy and disease-specific, overall, or pulmonary progression-free survival. CONCLUSIONS. Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.

AB - BACKGROUND. The benefit of chemotherapy in the treatment of primary soft-tissue sarcoma (STS) is controversial. To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity. METHODS. Between 1990 and 2005, 1897 patients with extremity STS were treated and prospectively followed at a single institution. In all, 508 patients (27%) developed lung metastases as the first site of distant recurrence, and 138 (7%) were treated with pulmonary resection. RESULTS. Perioperative chemotherapy was administered to 53 patients (38%). Age at diagnosis and disease-free interval were significantly different between patients who received perioperative chemotherapy and those who did not, whereas sex, grade, size of the primary tumor, depth, histology, number and size of lung metastases, and rate of complete resection were not. The median post-metastasis disease-specific survival was 24 months in patients who were treated with surgery and chemotherapy compared with 33 months in patients who were treated with surgery alone (P = .19). The median postmetastasis pulmonary progression-free survival in the 2 groups was 10 months and 11 months, respectively (P = .63). Multivariate Cox proportional hazards modeling and propensity score analysis revealed no association between perioperative chemotherapy and disease-specific, overall, or pulmonary progression-free survival. CONCLUSIONS. Although it is difficult to completely control for the effects of selection bias on outcome in this highly selected cohort of patients, data from the current study suggest that systemic chemotherapy has minimal, if any, long-term impact on the outcome of patients undergoing pulmonary resection for metastatic STS of the extremity.

KW - Long-term impact

KW - Perioperative chemotherapy

KW - Pulmonary metastasectomy

KW - Soft-tissue sarcoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=35648941713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648941713&partnerID=8YFLogxK

U2 - 10.1002/cncr.23023

DO - 10.1002/cncr.23023

M3 - Article

VL - 110

SP - 2050

EP - 2060

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -